By VETTAPHARMA reporter – Derek Roche: Eli Lilly and Company’s Omvoh (mirikizumab-mrkz) continues to demonstrate durable efficacy as the first and only IL-23p19 inhibitor to show long-term disease control in inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease.
Clinical data from the Phase III VIVID-1 and VIVID-2 trials showed that more than 90% of patients who achieved steroid-free remission at one year maintained remission through three years of treatment in Crohn’s disease.
Additional findings from the LUCENT-3 study in ulcerative colitis demonstrated sustained disease control for up to four years, with 63.5% of patients maintaining disease clearance after achieving it at one year.
Omvoh is indicated for adults with moderately to severely active ulcerative colitis and Crohn’s disease, targeting the IL-23 pathway, a key driver of chronic inflammation in these conditions.
The consistent efficacy across multiple Phase III programmes reinforces Lilly’s strategy of advancing durable, long-term disease-modifying therapies in immunology, focusing on sustained remission rather than short-term symptom control.
For patients, these results indicate the potential for long-term remission with reduced dependence on corticosteroids, fewer hospitalizations, and lower likelihood of surgery, addressing major unmet needs in chronic inflammatory bowel diseases.
From a commercial perspective, the strong long-term data and differentiated positioning of Omvoh as a first-in-class IL-23p19 inhibitor with multi-year efficacy support continued growth potential, particularly as treatment paradigms shift toward durable disease control and earlier intervention.
